id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-N-1307-0024,FDA,FDA-2020-N-1307,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals,Notice,Notice of Approval,2021-12-30T05:00:00Z,2021,12,2021-12-30T05:00:00Z,,2021-12-30T14:32:10Z,2021-28362,0,0,0900006484f005cf
FDA-2020-N-1307-0021,FDA,FDA-2020-N-1307,Reference 12 Fisher re: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Examination of Secondary Claim Disclosures and Biosimilar Disclosures in Prescription Drug Promotional Materials,Supporting & Related Material,Background Material,2021-09-15T04:00:00Z,2021,9,,,2021-09-15T13:28:46Z,,0,0,0900006484d80e98
FDA-2020-N-1307-0017,FDA,FDA-2020-N-1307,Reference 8 re: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Examination of Secondary Claim Disclosures and Biosimilar Disclosures in Prescription Drug Promotional Materials,Supporting & Related Material,Background Material,2021-09-15T04:00:00Z,2021,9,,,2021-09-15T13:22:03Z,,0,0,0900006484d80e94
FDA-2020-N-1307-0019,FDA,FDA-2020-N-1307,Reference 10 re: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Examination of Secondary Claim Disclosures and Biosimilar Disclosures in Prescription Drug Promotional Materials,Supporting & Related Material,Background Material,2021-09-15T04:00:00Z,2021,9,,,2021-09-15T13:26:01Z,,0,0,0900006484d80e96
FDA-2020-N-1307-0023,FDA,FDA-2020-N-1307,Reference 14 re: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Examination of Secondary Claim Disclosures and Biosimilar Disclosures in Prescription Drug Promotional Materials,Supporting & Related Material,Background Material,2021-09-15T04:00:00Z,2021,9,,,2021-09-15T13:31:43Z,,0,0,0900006484d81167
FDA-2020-N-1307-0018,FDA,FDA-2020-N-1307,Reference 9 re: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Examination of Secondary Claim Disclosures and Biosimilar Disclosures in Prescription Drug Promotional Materials,Supporting & Related Material,Background Material,2021-09-15T04:00:00Z,2021,9,,,2021-09-15T13:24:03Z,,0,0,0900006484d80e95
FDA-2020-N-1307-0020,FDA,FDA-2020-N-1307,Reference 11 re: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Examination of Secondary Claim Disclosures and Biosimilar Disclosures in Prescription Drug Promotional Materials,Supporting & Related Material,Background Material,2021-09-15T04:00:00Z,2021,9,,,2021-09-15T13:27:38Z,,0,0,0900006484d80e97
FDA-2020-N-1307-0022,FDA,FDA-2020-N-1307,Reference 13 re: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Examination of Secondary Claim Disclosures and Biosimilar Disclosures in Prescription Drug Promotional Materials,Supporting & Related Material,Background Material,2021-09-15T04:00:00Z,2021,9,,,2021-09-15T13:30:08Z,,0,0,0900006484d81166
FDA-2020-N-1307-0016,FDA,FDA-2020-N-1307,"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Examination of Secondary Claim Disclosures and
Biosimilar Disclosures in Prescription Drug Promotional Materials",Notice,30 Day Proposed Information Collection,2021-09-13T04:00:00Z,2021,9,2021-09-13T04:00:00Z,2021-10-14T03:59:59Z,2021-09-13T13:42:26Z,2021-19690,0,0,0900006484d75b41